Concepts (205)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antineoplastic Combined Chemotherapy Protocols | 21 | 2025 | 2642 | 1.250 |
Why?
|
| Breast Neoplasms | 18 | 2024 | 3147 | 1.110 |
Why?
|
| Pyridines | 8 | 2021 | 319 | 1.070 |
Why?
|
| Triple Negative Breast Neoplasms | 6 | 2025 | 184 | 0.940 |
Why?
|
| Kidney Neoplasms | 7 | 2019 | 558 | 0.780 |
Why?
|
| Antineoplastic Agents | 8 | 2018 | 2422 | 0.690 |
Why?
|
| Receptor, ErbB-2 | 6 | 2023 | 280 | 0.680 |
Why?
|
| Carcinoma, Renal Cell | 5 | 2019 | 367 | 0.610 |
Why?
|
| Neoadjuvant Therapy | 8 | 2024 | 444 | 0.570 |
Why?
|
| Capecitabine | 4 | 2024 | 99 | 0.560 |
Why?
|
| Benzenesulfonates | 2 | 2008 | 50 | 0.540 |
Why?
|
| Chemotherapy, Adjuvant | 7 | 2024 | 518 | 0.420 |
Why?
|
| Watchful Waiting | 3 | 2024 | 71 | 0.400 |
Why?
|
| Enzyme Inhibitors | 2 | 2007 | 657 | 0.400 |
Why?
|
| Carcinoma, Small Cell | 2 | 2017 | 137 | 0.380 |
Why?
|
| Prostatic Neoplasms | 5 | 2022 | 1798 | 0.370 |
Why?
|
| Comparative Effectiveness Research | 1 | 2012 | 56 | 0.370 |
Why?
|
| Lung Neoplasms | 5 | 2018 | 2463 | 0.370 |
Why?
|
| Urologic Neoplasms | 2 | 2024 | 78 | 0.370 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2024 | 244 | 0.340 |
Why?
|
| Middle Aged | 32 | 2025 | 28363 | 0.340 |
Why?
|
| Bevacizumab | 8 | 2022 | 276 | 0.330 |
Why?
|
| Aged | 28 | 2025 | 20964 | 0.330 |
Why?
|
| Students, Medical | 3 | 2023 | 455 | 0.320 |
Why?
|
| Neoplasms | 6 | 2023 | 3250 | 0.320 |
Why?
|
| Neoplasm Staging | 11 | 2025 | 2081 | 0.310 |
Why?
|
| Medical Oncology | 3 | 2019 | 408 | 0.310 |
Why?
|
| Radiosurgery | 3 | 2021 | 316 | 0.310 |
Why?
|
| Aged, 80 and over | 17 | 2024 | 7232 | 0.310 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2016 | 935 | 0.310 |
Why?
|
| Receptors, Estrogen | 3 | 2024 | 417 | 0.300 |
Why?
|
| Anilides | 3 | 2019 | 46 | 0.300 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2018 | 1172 | 0.280 |
Why?
|
| Humans | 50 | 2025 | 96127 | 0.280 |
Why?
|
| Female | 35 | 2025 | 50063 | 0.270 |
Why?
|
| Receptors, Progesterone | 2 | 2019 | 195 | 0.270 |
Why?
|
| Prostatectomy | 2 | 2021 | 480 | 0.260 |
Why?
|
| Bone Neoplasms | 2 | 2019 | 320 | 0.250 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2006 | 63 | 0.250 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2007 | 303 | 0.240 |
Why?
|
| Adult | 23 | 2025 | 28718 | 0.240 |
Why?
|
| Pyrroles | 2 | 2017 | 172 | 0.240 |
Why?
|
| Disease-Free Survival | 7 | 2024 | 1195 | 0.230 |
Why?
|
| Education, Medical, Undergraduate | 2 | 2019 | 189 | 0.220 |
Why?
|
| Indoles | 2 | 2017 | 317 | 0.220 |
Why?
|
| Neutropenia | 3 | 2021 | 218 | 0.220 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2024 | 1469 | 0.220 |
Why?
|
| Nitriles | 3 | 2024 | 157 | 0.220 |
Why?
|
| Trastuzumab | 2 | 2021 | 88 | 0.210 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2021 | 611 | 0.200 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2024 | 382 | 0.200 |
Why?
|
| Piperazines | 2 | 2021 | 296 | 0.200 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2024 | 156 | 0.200 |
Why?
|
| Aspirin | 1 | 2024 | 169 | 0.190 |
Why?
|
| Androgen Antagonists | 2 | 2021 | 144 | 0.190 |
Why?
|
| Neoplasm Invasiveness | 1 | 2024 | 590 | 0.190 |
Why?
|
| Vegetables | 2 | 2020 | 50 | 0.190 |
Why?
|
| Interdisciplinary Studies | 2 | 2019 | 20 | 0.180 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2024 | 249 | 0.180 |
Why?
|
| ErbB Receptors | 1 | 2005 | 513 | 0.180 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2024 | 226 | 0.180 |
Why?
|
| Schools, Medical | 2 | 2023 | 144 | 0.180 |
Why?
|
| Paclitaxel | 5 | 2025 | 498 | 0.180 |
Why?
|
| Oxazoles | 1 | 2021 | 18 | 0.180 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2023 | 111 | 0.180 |
Why?
|
| Clinical Competence | 2 | 2018 | 854 | 0.180 |
Why?
|
| Double-Blind Method | 5 | 2024 | 1791 | 0.170 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2024 | 1020 | 0.170 |
Why?
|
| Oncologists | 1 | 2021 | 38 | 0.170 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2021 | 154 | 0.170 |
Why?
|
| Postmenopause | 2 | 2024 | 107 | 0.170 |
Why?
|
| Male | 21 | 2024 | 45870 | 0.170 |
Why?
|
| Triazoles | 2 | 2024 | 110 | 0.170 |
Why?
|
| Quinazolines | 1 | 2021 | 216 | 0.160 |
Why?
|
| Leukemia | 1 | 2022 | 328 | 0.160 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2020 | 209 | 0.160 |
Why?
|
| Testosterone | 1 | 2021 | 277 | 0.150 |
Why?
|
| Treatment Outcome | 9 | 2025 | 9173 | 0.150 |
Why?
|
| Neoplasm Metastasis | 4 | 2016 | 1103 | 0.150 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2019 | 126 | 0.140 |
Why?
|
| Palliative Medicine | 1 | 2018 | 11 | 0.140 |
Why?
|
| Age Factors | 1 | 2023 | 1963 | 0.140 |
Why?
|
| Diet | 2 | 2022 | 461 | 0.140 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2021 | 299 | 0.140 |
Why?
|
| Counseling | 1 | 2020 | 174 | 0.140 |
Why?
|
| Survival Analysis | 4 | 2021 | 1546 | 0.140 |
Why?
|
| Prospective Studies | 5 | 2023 | 4671 | 0.140 |
Why?
|
| Niacinamide | 2 | 2008 | 102 | 0.130 |
Why?
|
| Disease Progression | 5 | 2021 | 1568 | 0.130 |
Why?
|
| Phenylurea Compounds | 2 | 2008 | 99 | 0.130 |
Why?
|
| Cyclooxygenase 2 | 1 | 2017 | 100 | 0.130 |
Why?
|
| Curriculum | 2 | 2019 | 615 | 0.130 |
Why?
|
| Survival Rate | 5 | 2019 | 1986 | 0.130 |
Why?
|
| Carboplatin | 4 | 2022 | 331 | 0.130 |
Why?
|
| Biomarkers, Tumor | 2 | 2020 | 1665 | 0.130 |
Why?
|
| Health Services Misuse | 1 | 2016 | 21 | 0.130 |
Why?
|
| Antibodies, Monoclonal | 2 | 2021 | 1431 | 0.130 |
Why?
|
| Patient-Centered Care | 1 | 2019 | 228 | 0.120 |
Why?
|
| Prognosis | 5 | 2023 | 4033 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2008 | 3651 | 0.120 |
Why?
|
| Follow-Up Studies | 5 | 2024 | 3927 | 0.120 |
Why?
|
| Needs Assessment | 1 | 2016 | 171 | 0.110 |
Why?
|
| Education, Medical, Graduate | 1 | 2018 | 436 | 0.100 |
Why?
|
| Pediatrics | 1 | 2018 | 399 | 0.100 |
Why?
|
| Area Under Curve | 2 | 2018 | 340 | 0.100 |
Why?
|
| Adenocarcinoma | 1 | 2020 | 1215 | 0.100 |
Why?
|
| Molecular Targeted Therapy | 2 | 2016 | 305 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2024 | 886 | 0.100 |
Why?
|
| Young Adult | 5 | 2024 | 7025 | 0.100 |
Why?
|
| Intensive Care Units | 1 | 2016 | 460 | 0.100 |
Why?
|
| Proportional Hazards Models | 2 | 2018 | 901 | 0.090 |
Why?
|
| Quality of Life | 4 | 2022 | 1816 | 0.090 |
Why?
|
| Intention to Treat Analysis | 2 | 2024 | 81 | 0.090 |
Why?
|
| Hospitalization | 1 | 2016 | 943 | 0.080 |
Why?
|
| Sirolimus | 1 | 2012 | 177 | 0.080 |
Why?
|
| Fatigue | 3 | 2017 | 185 | 0.080 |
Why?
|
| Clinical Trials as Topic | 2 | 2021 | 1178 | 0.070 |
Why?
|
| Combined Modality Therapy | 2 | 2023 | 1773 | 0.070 |
Why?
|
| Internship and Residency | 1 | 2018 | 1134 | 0.070 |
Why?
|
| Placebos | 1 | 2008 | 213 | 0.070 |
Why?
|
| Gadolinium DTPA | 1 | 2008 | 255 | 0.070 |
Why?
|
| Oncogenes | 1 | 2007 | 100 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2024 | 1973 | 0.060 |
Why?
|
| Prostate-Specific Antigen | 2 | 2020 | 346 | 0.060 |
Why?
|
| Retrospective Studies | 4 | 2024 | 10286 | 0.060 |
Why?
|
| Pandemics | 2 | 2023 | 880 | 0.060 |
Why?
|
| Deoxycytidine | 2 | 2021 | 215 | 0.060 |
Why?
|
| Cell Cycle | 1 | 2007 | 518 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2019 | 938 | 0.060 |
Why?
|
| Mifepristone | 1 | 2025 | 50 | 0.060 |
Why?
|
| Thrombocytopenia | 2 | 2017 | 191 | 0.050 |
Why?
|
| Albumins | 1 | 2025 | 135 | 0.050 |
Why?
|
| Ki-67 Antigen | 1 | 2024 | 67 | 0.050 |
Why?
|
| Drug Administration Schedule | 2 | 2016 | 873 | 0.050 |
Why?
|
| United States | 3 | 2024 | 7767 | 0.050 |
Why?
|
| Canada | 1 | 2024 | 215 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2023 | 3107 | 0.050 |
Why?
|
| Risk Factors | 3 | 2020 | 5960 | 0.050 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2025 | 144 | 0.050 |
Why?
|
| Contrast Media | 1 | 2008 | 1096 | 0.050 |
Why?
|
| Abiraterone Acetate | 1 | 2023 | 11 | 0.050 |
Why?
|
| Cancer Survivors | 1 | 2024 | 87 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2024 | 688 | 0.050 |
Why?
|
| Prednisone | 1 | 2023 | 258 | 0.050 |
Why?
|
| B7-H1 Antigen | 1 | 2024 | 305 | 0.050 |
Why?
|
| Mastectomy, Segmental | 1 | 2023 | 108 | 0.050 |
Why?
|
| Time Factors | 2 | 2021 | 5585 | 0.050 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2023 | 315 | 0.050 |
Why?
|
| Ipilimumab | 1 | 2021 | 64 | 0.040 |
Why?
|
| Surveys and Questionnaires | 2 | 2021 | 2860 | 0.040 |
Why?
|
| Radiation Oncologists | 1 | 2021 | 15 | 0.040 |
Why?
|
| Breast | 1 | 2023 | 297 | 0.040 |
Why?
|
| Patient Care Planning | 1 | 2021 | 89 | 0.040 |
Why?
|
| Neoplasm, Residual | 1 | 2022 | 194 | 0.040 |
Why?
|
| Ferredoxin-NADP Reductase | 1 | 2020 | 15 | 0.040 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2020 | 28 | 0.040 |
Why?
|
| Perception | 1 | 2021 | 185 | 0.040 |
Why?
|
| Learning | 1 | 2023 | 305 | 0.040 |
Why?
|
| Telephone | 1 | 2020 | 36 | 0.040 |
Why?
|
| Hypertension | 2 | 2017 | 777 | 0.040 |
Why?
|
| Mastectomy | 1 | 2021 | 270 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 1 | 2019 | 271 | 0.040 |
Why?
|
| Neovascularization, Pathologic | 1 | 2021 | 355 | 0.040 |
Why?
|
| Health Personnel | 1 | 2021 | 241 | 0.040 |
Why?
|
| Cisplatin | 1 | 2021 | 611 | 0.040 |
Why?
|
| Prostate | 1 | 2022 | 423 | 0.040 |
Why?
|
| Tamoxifen | 1 | 2019 | 171 | 0.040 |
Why?
|
| Training Support | 1 | 2018 | 23 | 0.040 |
Why?
|
| Consolidation Chemotherapy | 1 | 2018 | 23 | 0.030 |
Why?
|
| Radiation Pneumonitis | 1 | 2018 | 23 | 0.030 |
Why?
|
| Hemoptysis | 1 | 2018 | 26 | 0.030 |
Why?
|
| Interprofessional Relations | 1 | 2019 | 128 | 0.030 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2017 | 35 | 0.030 |
Why?
|
| Celecoxib | 1 | 2017 | 33 | 0.030 |
Why?
|
| Dinoprostone | 1 | 2017 | 74 | 0.030 |
Why?
|
| Pemetrexed | 1 | 2017 | 76 | 0.030 |
Why?
|
| Platinum Compounds | 1 | 2017 | 28 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2018 | 270 | 0.030 |
Why?
|
| Mucositis | 1 | 2017 | 18 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2020 | 381 | 0.030 |
Why?
|
| Educational Measurement | 1 | 2019 | 246 | 0.030 |
Why?
|
| Drug Eruptions | 1 | 2017 | 35 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2018 | 323 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2007 | 3586 | 0.030 |
Why?
|
| Maintenance Chemotherapy | 1 | 2017 | 91 | 0.030 |
Why?
|
| Selection Bias | 1 | 2016 | 38 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2018 | 713 | 0.030 |
Why?
|
| Anemia | 1 | 2017 | 137 | 0.030 |
Why?
|
| Standard of Care | 1 | 2016 | 70 | 0.030 |
Why?
|
| Genotype | 1 | 2020 | 1882 | 0.030 |
Why?
|
| Transcriptome | 1 | 2020 | 770 | 0.030 |
Why?
|
| Terminal Care | 1 | 2016 | 146 | 0.030 |
Why?
|
| Biomarkers | 1 | 2021 | 1933 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2014 | 313 | 0.030 |
Why?
|
| Incidence | 1 | 2018 | 1715 | 0.030 |
Why?
|
| Biopsy | 1 | 2017 | 1220 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2014 | 304 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2020 | 2480 | 0.020 |
Why?
|
| Remission Induction | 1 | 2014 | 769 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2020 | 2494 | 0.020 |
Why?
|
| MicroRNAs | 1 | 2016 | 592 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2011 | 555 | 0.020 |
Why?
|
| Child | 1 | 2018 | 7626 | 0.020 |
Why?
|
| Chicago | 1 | 2011 | 1503 | 0.020 |
Why?
|
| Mutation | 1 | 2012 | 4374 | 0.010 |
Why?
|